National Institute of Public Health, Wako-shi, Saitama, Japan.
Expert Rev Pharmacoecon Outcomes Res. 2010 Feb;10(1):17-24. doi: 10.1586/erp.09.70.
Reports that oseltamivir causes abnormal behaviors in influenza patients and, thereby, increases the risk of injuries or death alerted the world. Such reports came almost exclusively from Japan, which consumes more than 75% of the world supply, even before the novel influenza pandemic started. The Japanese government will not revoke its warning issued in March 2007 against the use of oseltamivir in teenagers despite the accumulating evidence that such abnormal behaviors are part of generic symptoms of influenza-like delirium and not attributable to certain drugs. The author analyzes the background of the 'ado' by compiling the various sources of information, some of which have not been readily available to the international audience and explains why Japan is incapable of producing firm evidence to draw a definite conclusion. The author also alarms the potential risk of sudden death related to oseltamivir and foresees how the problem may be solved in the future.
有关奥司他韦会导致流感患者出现异常行为，从而增加受伤或死亡风险的报告引起了全球关注。这些报告几乎全部来自日本，甚至在新型流感大流行开始之前，日本就消耗了全球供应量的 75%以上。尽管越来越多的证据表明，这种异常行为是流感样谵妄的一般症状的一部分，而不是归因于某些特定药物，但日本政府仍不会撤销其在 2007 年 3 月发布的针对青少年使用奥司他韦的警告。作者通过编译各种来源的信息来分析“ado”的背景，其中一些信息国际受众难以获取，并解释了为什么日本无法提供确凿的证据来得出明确的结论。作者还警告了与奥司他韦相关的猝死风险，并预测了未来如何解决这个问题。
